Kjell Bergfeldt

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Breast cancer risk in women with a primary ovarian cancer--a case-control study
    K Bergfeldt
    Department of Medical Epidemiology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Eur J Cancer 37:2229-34. 2001
  2. ncbi Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study
    Kjell Bergfeldt
    Department of Medical Epidemiology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Lancet 360:891-4. 2002
  3. ncbi Predictors of ovarian cancer survival: a population-based prospective study in Sweden
    Ling Yang
    Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom
    Int J Cancer 123:672-9. 2008
  4. ncbi p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer
    Debra G B Leonard
    Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Clin Cancer Res 8:973-85. 2002
  5. ncbi Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
    Luigi De Petris
    Department of Oncology, Radiumhemmet, Karolinska Hospital, 17176 Stockholm, Sweden
    Med Oncol 21:49-52. 2004
  6. ncbi Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer
    Zaynab Gamzatova
    Department of Oncology-Pathology, Karolinska Institute, Radiumhemmet, P301057 Karolinska University Hospital, 17176 Stockholm, Sweden
    Gynecol Oncol 103:145-50. 2006
  7. ncbi Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival
    Chantal Mascarenhas
    Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
    Int J Cancer 119:2907-15. 2006

Collaborators

Detail Information

Publications7

  1. ncbi Breast cancer risk in women with a primary ovarian cancer--a case-control study
    K Bergfeldt
    Department of Medical Epidemiology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Eur J Cancer 37:2229-34. 2001
    ....
  2. ncbi Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study
    Kjell Bergfeldt
    Department of Medical Epidemiology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Lancet 360:891-4. 2002
    ..Because these mutations are rare, easily obtained information such as age and family history of breast or ovarian cancer might be preferable for assessment of ovarian cancer risk in clinical practice...
  3. ncbi Predictors of ovarian cancer survival: a population-based prospective study in Sweden
    Ling Yang
    Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom
    Int J Cancer 123:672-9. 2008
    ....
  4. ncbi p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer
    Debra G B Leonard
    Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Clin Cancer Res 8:973-85. 2002
    ..The propensity for G-to-A transitions may reflect specific DNA damage in leukemias after treatment with platinum analogues...
  5. ncbi Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
    Luigi De Petris
    Department of Oncology, Radiumhemmet, Karolinska Hospital, 17176 Stockholm, Sweden
    Med Oncol 21:49-52. 2004
    ..Moreover, this fact would suggest different strategies for specific immunotherapy in addition to first line conventional treatments...
  6. ncbi Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer
    Zaynab Gamzatova
    Department of Oncology-Pathology, Karolinska Institute, Radiumhemmet, P301057 Karolinska University Hospital, 17176 Stockholm, Sweden
    Gynecol Oncol 103:145-50. 2006
    ..This finding has implications for clinical patient management. Association with known oncogenes needs further analysis...
  7. ncbi Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival
    Chantal Mascarenhas
    Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
    Int J Cancer 119:2907-15. 2006
    ..Women using HRT after diagnosis had a better survival than women with no use, but we cannot rule out that this latter finding may reflect a subtle selection process...